Nektar Therapeutics just saw its fair value model refreshed, with the headline number holding steady at US$114.43 per share even as the long term revenue growth assumption for Rezpeg edged to a 10.83% ...

At CES 2026, Nvidia Corp. Chief Executive Jensen Huang once again reset the economics of artificial intelligence factories.

Beena Wood, Qinecsa, saw 2025 as an AI superposition in which pharmacovigilence needed better data foundations and regulation ...

The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

The Bristlemoon Global Fund achieved an 11.9 percent cumulative return since inception despite recent quarterly volatility.

Longer-term results from the BENEFIT trial show sustained minimal residual disease negativity in newly diagnosed, ...

CK0804, a novel Treg therapy, gains FDA orphan drug status for myelofibrosis, promising new hope for patients with limited treatment options. CK0804, an investigational allogeneic regulatory T cell ...

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

In short, the footage did not show people in Venezuela. While it was correct that the scene depicted people celebrating ...

Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

Valuing a business to sell can seem daunting to many owners. IRAEmpire aims to help with their business valuation guide. ORLANDO, FLORIDA / ACCESS Newswire / January 10, 2026 / Before putting a busine ...